Evaluation of anti-viral activity of Jatropha curcas leaf extracts against potentially drug-resistant HIV isolates
BMC Infectious Diseases volume 12, Article number: P14 (2012)
Drug-resistant HIV, a major global concern, warrants the development of novel anti-virals as alternative and inexpensive therapy. In the current study, we isolated potentially drug-resistant HIV and assessed previously unreported anti-viral activity of Jatropha curcas leaf extracts.
In vitro micro-co-culture was employed for virus isolation followed by drug susceptibility assays to determine resistance to Azidothymidine (AZT) and Lamivudine (3TC).
Jatropha curcasleaves were extracted using Soxhlet apparatus. Methanolic (ME) and aqueous (AE) extracts were chosen for further study. Secondary metabolites were detected by High-Performance Thin Laye rChromatography and in vitro cytotoxicity established by MTT assay. Anti-viral activity was evaluated by p24 inhibitionin post- and pre-infection interaction studies.
Seven HIV isolates were obtained (isolation rate: 23.33%) with drug IC50 values ranging from 0.001418-82.73 µM AZT and 2.645-15.35 µM 3TC.
Tannins, flavonoids, saponins were detected in AE and flavonoids, saponins in ME while CC50 values were 32.07 mg/mL AE and 35.5 mg/mL ME.
In post-infection studies (4 isolates), IC50 values were ranging from 0.0255-0.4137 mg/mL AE and 0.00073-0.1278 mg/mL ME; pre-infection studies (1 isolate) showed 100% p24 inhibition by ME and 97.19% p24 inhibition by AE at 25 mg/mL each.
HIV isolates potentially resistant to AZT/3TC were obtained; genotypic drug resistance is being ascertained. Jatropha curcas leaf extracts showed effective anti-viral and probable entry inhibition activity against potentially drug-resistant HIV, which has not been reported earlier. We conclude that Jatropha curcasis a good candidate for anti-HIV therapy with further research.
About this article
Cite this article
Dahake, R., Roy, S., Patil, D. et al. Evaluation of anti-viral activity of Jatropha curcas leaf extracts against potentially drug-resistant HIV isolates. BMC Infect Dis 12 (Suppl 1), P14 (2012). https://doi.org/10.1186/1471-2334-12-S1-P14